Retro Biosciences, headquartered in United States, remains privately held in the biotechnology space. Investors last valued the company at $1.8B. No public ticker exists for the company.
1 valuation. The latest, $1.8B post-money, was set by the Series B in May 2026.
Stripe, Y CombinatorRetro Biosciences develops therapies that meaningfully reverse age-related diseases, aiming to add ten years to healthy human lifespan. The company focuses on cellular drivers of aging, including tissue reprogramming and chemical rejuvenation, to design therapeutics intended to eventually prevent and reverse age-related disease.
Retro frames its mission against the scale of US healthcare spending, noting that roughly 90% of that spending, over $3 trillion, goes toward age-related diseases. It describes its work as going from proof of concept to clinical translation.
Listed funds carry late-stage private names. A fund's latest schedule of investments shows whether it holds Retro Biosciences.
Often trade at a premium or discount to NAV.
Platforms match existing holders with buyers. Retro Biosciences availability at any moment is set by the holders.
High minimums, transfer approval, company right-of-first-refusal.
Valuations, rounds and IPO status for every company in the directory — Retro Biosciences included.
The last valuation is $1.8B.
Lead investors for each round are in the funding timeline.
The closest biotechnology peers are on the competitors page.
The routes section explains what is realistically available for a company at this stage.
No. Retro Biosciences is a private company; its shares do not trade on a public exchange.
Perpetual markets for stocks, gold, indices and pre-IPO names — settled on-chain, no wallet-to-exchange transfers.
